摘要
目的观察单用二甲双胍血糖控制不佳的早期2型糖尿病(T2DM)患者加用二肽基肽酶-Ⅳ(DPP-4)抑制剂西格列汀治疗的疗效及安全性。方法选择病程3年以内、单用二甲双胍治疗3个月以上、血糖控制不良的T2DM患者24例,加用西格列汀100 mg/d,持续治疗12周,观察治疗前后空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、体质量的变化情况。结果加用西格列汀治疗12周后,FPG、2hPG、HbA1c较前显著下降(P<0.01),体质量无显著变化(P>0.05),治疗期间无严重不良反应发生。结论单用二甲双胍控制不良的早期T2DM患者加用西格列汀安全、有效,患者耐受性好。
Objective To observe the eifficacy and safety of dipeptidyl peptidase-4 inhibitor Sitagliptin added to patients with early type 2 diabetes inadequately controlled by metformin alone.Methods 24 patients inadequately controlled with Metformin were enrolled and added with Sitagliptin 100mg once daily for 12 weeks.The levels of fasting plasma glucose（FPG）,2 hours postprandial glucose（2hPG）,hemoglobin A1c（HbA1c） and weight were compared after treatment.Results FPG,2hPG and HbA1c reduced significantly after treatment of sitagliptin（P 0.01）.There was not serious adverse effect happened.Conclusion Sitagliptin added to ongo metformin therapy is efficacious and safe.
出处
《中国临床保健杂志》
CAS
2013年第4期363-364,共2页
Chinese Journal of Clinical Healthcare
关键词
糖尿病
2型
二甲双胍
治疗结果
西格列汀
Diabetes mellitus
type 2
Metformin
Treatment outcome
Sitagliptin
